Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database. - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Annals of the Rheumatic Diseases Année : 2020

Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.

Résumé

As shown by Kostine et al,1 and recently underlined by Ceccarelli et al,2 rheumatic inflammatory disorders induced by anticancer therapy are becoming a major concern for rheumatologists at the era of immune checkpoint inhibitors (ICIs). Beyond inflammatory arthritis, which may concern 10%–20% of patients, myositis represents a rare (<1%) but potentially life-threatening event. We thus aimed at investigating the risk of ICI-related myositis in real-life setting using VigiBase, the WHO’s pharmacovigilance database.
Fichier principal
Vignette du fichier
10.1136annrheumdis-2020-217018 Myositis ICI - 20200116 ARD correspondence - JLF.pdf (115.47 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03515309 , version 1 (07-04-2022)

Identifiants

Citer

Thủy Nguyễn, Alexandre Thibault Jacques Maria, Chayma Ladhari, Pascale Palassin, Xavier Quantin, et al.. Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.. Annals of the Rheumatic Diseases, 2020, pp.annrheumdis-2020-217018. ⟨10.1136/annrheumdis-2020-217018⟩. ⟨hal-03515309⟩
80 Consultations
72 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More